Sutro Biopharma, Inc. (STRO)

Sutro Biopharma's stock (STRO) has experienced significant volatility and events in the past six months (July 2025 - January 2026). As of January 2, 2026, the stock price was $10.96 per share, representing a decline of 43.79% from January 3, 2025. Over the last 12 months, the stock's price decreased by 38.76%, but in the past month, the stock increased by 15.26%. Key events impacting the stock include a 1-for-10 reverse stock split, Q2 2025 financial results, Q3 2025 financial results, and analyst price target changes.

Information regarding specific demand seasonality for Sutro Biopharma, Inc.'s products and services is not readily available. As a clinical-stage biopharmaceutical company focused on drug discovery and development, its revenue is primarily driven by collaborations and milestone payments rather than direct product sales to end-users, which typically exhibit seasonality. Therefore, traditional demand seasonality for products and services may not be directly applicable to Sutro Biopharma.

Sutro Biopharma, Inc. is a publicly traded clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California, operating in the Biotechnology and Pharmaceutical industries with a focus on oncology therapeutics. Sutro Biopharma utilizes its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+, to develop next-generation protein therapeutics for cancer and autoimmune disorders. Its major product candidates are antibody-drug conjugates (ADCs), including STRO-001, STRO-002, STRO-004, and STRO-006. The company also has a dual-payload ADC program with an IND filing anticipated in 2027. Previously, luveltamab tazevibulin (luvelta) was being evaluated in Phase 2/3 trials, but its prioritization was shifted in March 2025.

Sutro Biopharma, Inc. has its corporate office in South San Francisco, California, and a manufacturing facility located in San Carlos, California. Both locations are in the San Francisco Bay Area.

Sutro Biopharma's brand reputation over the past year has likely been significantly impacted by a major strategic shift and restructuring announced in March 2025. Key events affecting its reputation include a strategic portfolio review and prioritization, leadership changes, workforce reduction, and manufacturing facility changes. These events, particularly the deprioritization of a lead candidate and substantial layoffs, could be perceived negatively by investors, employees, and the broader scientific community, potentially affecting the company's reputation for stability and consistent pipeline development.

Sutro Biopharma, Inc. has 148 institutional owners and shareholders holding a total of 54,826,059 shares. Major institutional owners include Suvretta Capital Management, Llc, Kynam Capital Management, LP, Millennium Management Llc, Vanguard Group Inc, Acadian Asset Management Llc, Velan Capital Investment Management LP, Tang Capital Management Llc, Merck & Co., Inc., Vestal Point Capital, LP, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Peter Kolchinsky is noted as owning the most shares among individuals.